Ensayos clínicos

Inclusion Criteria:

• ≥ 18 years of age.
• Has a documented diagnosis of ACTH-dependent, endogenous Cushing's syndrome and is scheduled for curative surgery.
• Must be able to comprehend and sign an approved Informed Consent Form (ICF) and other applicable study enrollment documents.

Exclusion Criteria:

• Plans for pre-operative and/or intra-operative use of glucocorticoid ("steroid cover").
• Use any of the following treatments for Cushing's syndrome, as specified:
  • 4 weeks prior to first specimen collection and/or during the study period.
    • Adrenostatic medications (metyrapone, ketoconazole, fluconazole, aminoglutethimide, LCI699 or etomidate etc).
    • Short-acting somatostatin analogs (octreotide, pasireotide).
  • 6 weeks prior to first specimen collection and/or during the study period.
    • Mifepristone.
  • 8 weeks prior to first specimen collection and/or during the study period. 
    • Neuromodulator drugs that act at the hypothalamic-pituitary level: serotonin antagonists (cyproheptadine, ketanserin, retanserin), dopamine agonists (bromocriptine, cabergoline), gamma-aminobutyric acid agonists (sodium valproate), and somatostatin receptor ligands (octreotide long-acting release [LAR], pasireotide LAR, lanreotide).
• Concomitant use of the following due to their potential to stimulate the expression of FKBP5:
  • Testosterone or other steroid hormone analogues.
  • Oral contraceptives or hormonal replacement therapy.
• History of illness that the Principal Investigator (PI) considers could interfere with or affect the conduct, results, and/or completion of the clinical trial.
• Pregnancy or breastfeeding.